Maria Karsas

Maria Karsas

Auto-generated profile, based on publicly available information

Maria Karsas

University of Pretoria, Department of Internal Medicine and Paediatrics, Steve Biko Academic Hospital, Pretoria, South Africa

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in IJID Regions
Verified
Journal Article
Open access
DMDavid Paul Moore
David Paul Moore
TCTerusha Chetty
Terusha Chetty
APAshendri Pillay
Ashendri Pillay
MKMaria Karsas
Maria Karsas
JCJeané Cloete
Jeané Cloete
PJPrakash Jeena
Prakash Jeena
South Africa implemented a National Strategic Framework to optimise antimicrobial stewardship in 2014; however, there is limited data on how this has affected prescribing, especially to children treated in academic centres. We conducted a point prevalence survey using the World Health Organization (WHO) methodology to evaluate antibiotic and antifungal prescribing practices in paediatric departments at three academic hospitals in South Africa. We recorded 1946 antimicrobial prescriptions in 1191 children, with 55.2% and 39.2% of the antibiotics classified as WHO AWaRe Access and Watch drugs, respectively. There were significant differences in prescription of Reserve antibiotics and antifungals between institutions. Receipt of WHO Watch and Reserve antibiotics was independently associated with infancy (<12 months) and adolescents (13-17 years) (adjusted relative risk [aRR]: 2.09-9.95); prolonged hospitalisation (aRR: 3.29-30.08); rapidly or ultimately fatal illness (aRR: 1.94 to 5.52); and blood transfusion (aRR: 3.28-5.70). Antifungal prescribing was associated with treatment of hospital-associated infection (aRR: 2.90), medical prophylaxis (aRR: 3.30), and treatment in intensive care units (aRR: 2.15-2.27). Guidance on optimisation of infection prevention and control practice and strengthening of antimicrobial stewardship would impact positively on the care of sick children in our setting.

16 July 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LMLorrein Muhwava
Lorrein Muhwava
Elena Marbán-CastroElena Marbán-Castro
Elena Marbán-Castro
MSMpho Silima
Mpho Silima
MKMaria Karsas
Maria Karsas
TKTanja Kemp
Tanja Kemp
SSSonjelle Shilton
Sonjelle Shilton
Background: Continuous Glucose Monitoring (CGM) is an advancement in diabetes management, offering real-time insights into blood glucose levels and facilitating decision-making around diabetes care. However, its adoption in low- and middle-income countries (LMICs) remains low. This study explored the perceptions and experiences of CGM use among people living with type 1 diabetes (T1D), their caregivers, and healthcare providers (HCPs) in the public sector in South Africa. Methods: Convenience sampling was used to recruit participants from the ACCEDE study – a pragmatic randomised controlled trial on CGM use among people living with T1D in South Africa. Between July 2024 and February 2025, we conducted focus group discussions (FGDs) with recipients of care and caregivers and semi-structured interviews (SSIs) with HCPs across study sites in Cape Town and Pretoria. All FGDs and SSIs were audio-recorded, transcribed, and analysed using MAXQDA 2022. Data analysis followed thematic content analysis, and the findings presented according to the socioecological framework. Results: A total of 107 participants, including 75 people living with T1D, 17 caregivers, and 15 HCPs, were included in the study. CGM was generally perceived as acceptable due to convenience, reduced need for finger-prick testing, and enhanced understanding of glucose patterns. Feasibility was enhanced by ease of use, access to training, and social support. Key barriers included cost, limited awareness, and socio-economic constraints such as food insecurity and lack of access to transport. Conclusion: CGMs are both feasible and acceptable within South Africa’s public healthcare context. However, integration requires a coordinated, multi-level response, strengthening provider and patient awareness, knowledge, adequately resourced multi-disciplinary diabetes care teams, and addressing affordability through supportive health policies.

31 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
Elena Marbán-CastroElena Marbán-Castro
Elena Marbán-Castro
LMLorrein Muhwava
Lorrein Muhwava
SGSarah Girdwood
Sarah Girdwood
TKTanja Kemp
Tanja Kemp
JFJohanè Freitas
Johanè Freitas
MKMaria Karsas
Maria Karsas
Introduction: Continuous glucose monitoring (CGM) offers an advancement over traditional self-monitoring of blood glucose (SMBG) for people living with type 1 diabetes (T1D). However, evidence on the acceptability and feasibility of different CGM use cases in African populations remains limited. Methods: This was a pragmatic three-arm, randomised controlled trial on CGM conducted among people living with T1D in three public healthcare clinics in South Africa. Participants were assigned to Arm 1 (continuous CGM), Arm 2 (periodic CGM), or Arm 3 (SMBG). Diabetes education was provided at all study visits. Feasibility was assessed by adherence to CGM use and through the Glucose Monitoring Satisfaction Survey (GMSS). Diabetes distress was measured by the Diabetes Distress Scale (DDS), health-related quality of life (HRQoL) by the EQ-5D scales, and acceptability using the Theoretical Framework of Acceptability (TFA). Surveys were collected on paper and transferred to OpenClinica. Analyses were performed in R. The trial was registered in the Clinical Trials Registry ( NCT05944718 ) on July 13, 2023. Results: A total of 83 participants were included in Arm 1, 85 in Arm 2, and 80 in Arm 3. CGM mean active time was 55% in Arm 1 versus 69% in Arm 2. The proportion of participants meeting the ≥70% active time threshold was higher in Arm 2 (52%) than in Arm 1 (34%). Diabetes’ distress declined across arms during the intervention period, with no significant difference between arms; distress increased slightly six months post-intervention but remained below baseline. At 6 months, glucose monitoring satisfaction was significantly higher in both CGM arms than in the SMBG arm, and satisfaction increased over time in CGM arms. Health-related quality of life remained stable across arms during the intervention period with no significant difference between arms. High acceptability was observed in both CGM arms, with higher ratings in the periodic arm. Conclusions: CGM was acceptable to people living with type 1 diabetes and feasible to use in public-sector clinics in South Africa, with high acceptability under continuous and periodic use. Health-related quality of life remained stable across arms, and diabetes-related distress declined, during the intervention period, across arms. Glucose monitoring satisfaction rose significantly in both CGM arms compared to SMBG. Periodic CGM might be a promising and potentially more scalable option than continuous use for public-sector care. Clinical Trials registration: NCT05944718

25 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JKJulia Kate Kirkby
Julia Kate Kirkby
EHEngela Magdalena Honey
Engela Magdalena Honey
RGRuan Goller
Ruan Goller
AMAndries Masenge
Andries Masenge
MKMaria Karsas
Maria Karsas
Background: Osteogenesis Imperfecta (OI) is a heterogenous heritable condition of bone that impairs bone quality. Data on the South African (SA) OI population, particularly treatment response to bisphosphonates (BP), are limited. This study evaluated the clinical profile, FKBP10 pathogenic variant prevalence and response to zoledronic acid (ZA) in children with OI. Methods: A retrospective cohort study was conducted in children aged 0-18 years with OI treated with ZA at Steve Biko Academic Hospital (SBAH) from January 2013 to June 2022. Findings: Forty patients were included: 2 (5%) had OI type 1, 1 (2∙5%) had OI type 2, and 37 (92∙5%) had OI type 3. Among patients with OI type 3, 18 (48∙6%) were FKBP10-positive and 18 (48∙6%) were FKBP10-negative; one was untested. The male-to-female ratio was 1∙35:1. Common clinical features included blue sclera (55%), dentinogenesis imperfecta (50%) and vitamin D insufficiency (25%). Before treatment, the most common fracture sites were the femur (33∙1%), humerus (12∙2%) and ribs (10∙5%), while tibial fractures predominated during treatment (16∙4%). The median annual fracture rate for all patients decreased from 1∙6 to 1∙0 fractures/year following ZA, representing a 38% reduction (p=0∙002). FKBP10–negative patients had a higher baseline fracture rate than FKBP10-positive patients (2∙4 vs 0∙9 fractures/year). ZA significantly reduced fractures in the FKBP10-negative subgroup (2∙4 to 0∙9 fractures/year; p=0∙003), whereas no significant improvement was observed in FKBP10-positive patients (0∙9 to 1∙1 fractures/year; p=0∙906). Patients who required surgery (29/40) had a mean of 2∙9 orthopaedic procedures per patient. Overall growth velocity was 7∙56 cm/year; although FKBP10-positive patients had significantly lower growth velocity (5∙95 cm/year; p=0∙005). Interpretation: The FKBP10 pathogenic variant is highly prevalent among SA children with OI type 3. ZA significantly reduced fracture rates overall but appeared less effective in patients with the FKBP10 pathogenic variant, suggesting genotype may influence treatment response. Larger prospective studies are needed to confirm these findings.

6 November 2024 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
PKPieter Willem Kriek
Pieter Willem Kriek
MKMaria Karsas
Maria Karsas
JCJeané Cloete
Jeané Cloete
Xanthogranulomatous pyelonephritis is a rare condition in paediatric patients, mostly described in middle-aged female patients. We present a 7-year-old female with juvenile idiopathic arthritis, who was found to have a kidney mass with a concurrent Escherichia coli urinary tract infection. Surgical excision was done out of concern for possible malignancy. Histology confirmed the diagnosis of xanthogranulomatous pyelonephritis and persistent E. coli infection.